Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Background

Meet Our Team

The Sygnature Discovery leadership team benefits from a diversity of backgrounds and significant industry experience & technical expertise.  In collaboration with the wider team, they are the driving force behind our success in drug discovery.

Loading…
Simon Hirst, PhD
Simon Hirst, PhD
Chief Executive Officer
Jonathan Williams, PhD
Jonathan Williams, PhD
Chief Resilience Officer
David Witty, PhD
David Witty, PhD
Chief Scientific Officer
Louisa Jordison
Louisa Jordison
Chief Financial Officer
James Edgar
James Edgar
Chief People Officer
Stuart Onions, PhD
Stuart Onions, PhD
Chief Technical Officer
Kieron Hall
Kieron Hall
Chief Commercial Officer
Jade Dagher
Jade Dagher
General Manager, North America
Malken Bayrakdarian
Malken Bayrakdarian
Vice President, Drug Discovery, North America
Emily Eaton, PhD
Emily Eaton, PhD
Vice President, Commercial Services
David Claveau
David Claveau
Vice President, Business Development, North America
David Dalrymple, PhD
David Dalrymple, PhD
Vice President, Business Development, Discovery Services
Nicholas Ayers
Nicholas Ayers
Vice President, Business Development, Europe
Amanda Davies, PhD
Amanda Davies, PhD
Vice President, Marketing
Andrew Novak, PhD
Andrew Novak, PhD
Associate Director, Drug Discovery Partnerships
Allan Jordan, PhD
Allan Jordan, PhD
Vice President, Oncology Drug Discovery
Max Mirza, PhD
Max Mirza, PhD
Vice President, Neuroscience Drug Discovery
Stephen Young, PhD
Stephen Young, PhD
Vice President, Hit ID Technologies
Fraser McIntosh
Fraser McIntosh
Vice President, Global in vivo Pharmacology
Claudio Sturino, PhD
Claudio Sturino, PhD
Senior Director, Chemistry
Geraint Jones, PhD
Geraint Jones, PhD
Director, Chemistry
Stephane Trudeau
Stephane Trudeau
Director Chemistry
Colin Sambrook Smith
Colin Sambrook Smith
Director, Computational Sciences and Informatics
Stuart Thomson, PhD
Stuart Thomson, PhD
Director, Bioscience
Yaël Mamane, PhD
Yaël Mamane, PhD
Senior BioCell Director
Lesley Gerrard, PhD
Lesley Gerrard, PhD
Director, Cellular Pharmacology
Rick Davies
Rick Davies
Director, Protein Sciences and Structural Biology
René Coulombe
René Coulombe
Senior Director, Protein Science
Alex Stevens, PhD
Alex Stevens, PhD
Director, DMPK
David Pearson, PhD
David Pearson, PhD
Director, Form and Formulation

Interested in joining our team?

At Sygnature Discovery we’re looking for people that share our passion for drug discovery research. We recruit great scientists with the same ambition to improve people’s health through their work. We offer varied careers across multiple drug discovery disciplines.

View Careers